Esma Saâda-Bouzid

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 596 citations

Oncology, Neoadjuvant Therapy, Anti-pd-1/pd-l1 Therapy +6

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

Olivier Mir, Thomas Brodowicz, Antoîne Italiano et al. · The Lancet Oncology · 2016 · 276 citations

Oncology, Metronomic Therapy, Clinical Trials +5

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial

Isabelle Laure Ray-Coquard, Julien Dômont, Emmanuelle Tresch‐Bruneel et al. · Journal of Clinical Oncology · 2015 · 188 citations · Full text